Done right, MedTech thought leadership can be one of the most effective ways to influence key stakeholders in 2026.
But most attempts fail to reach their target audience.
In this article, we'll explore the reasons why MedTech companies struggle to build influence through thought leadership, which content channels actually reach the people that matter, and how to design a communications strategy that produces tangible results.
Why most MedTech thought leadership doesn't land
Most attempts at MedTech thought leadership fail to build influence because they target the wrong channels with the wrong type of content.
The health sector is distinct from other B2B markets.
For MedTech thought leadership to succeed, the target audience must view the content as credible. Decision-makers in the health sector, including NHS commissioners, NICE appraisal committees, and clinical procurement leads, deliberately seek information backed by clinical evidence and peer-reviewed sources.
Generic B2B marketing advice might recommend prioritising high-volume content on platforms such as LinkedIn, but UK MedTech companies need a different approach.
Why?
Because the MedTech sector is held to higher standards. It’s regulated by the MHRA and evaluated against clinical and cost-effectiveness thresholds set by NICE.
UK MedTech spend and adoption decisions are increasingly made by integrated care boards (ICBs) rather than individual trusts, further concentrating the audience and raising the bar for relevance. See NHS guidance on the newly implemented Value Based Procurement (VBP) system for more information on how MedTech procurement decisions are made (published June 2026).
Commentary that ignores clinical evidence conventions, such as LinkedIn-style marketing content, rarely passes this audience’s credibility filter and struggles to build influence with the people that matter.
In the next section, we’ll explore how you can use peer-reviewed commentary and clinical research to strengthen your thought leadership strategy.
Peer-reviewed commentary and clinical publication: the highest-trust channel.
For MedTech thought leaders, contribution to peer-reviewed journals and named clinical publications is the most effective way to build influence among NHS procurement leads and clinicians.
This is because publications like the BMJ or the Lancet maintain high evidentiary standards and are widely perceived as credible by sector professionals.
Peer-reviewed engagement is becoming more commercially relevant than ever. MedTech companies must comply with NICE’s Evidence Standards Framework for Digital Technologies, and content that falls outside these guidelines is quickly dismissed.
Where a bylined piece in a peer-reviewed journal signals independence from commercial interest, a LinkedIn post reads as poorly disguised marketing content.
What counts as high-trust content?
High-trust content encompasses more than just original research.
Conducting original research can be unrealistic for smaller MedTech companies facing time and resource constraints. Fortunately, high-trust content encompasses a range of material.
Often overlooked in PR planning, rapid responses, correspondence columns, and commentary pieces can be realistic entry points for a communications team supporting a clinical spokesperson in thought leadership.
Consult BMJ guidelines for more information on what constitutes an eligible rapid response or commentary submission.
But clinical expertise remains critical.
MedTech thought leadership is more successful when delivered by a credible clinical voice. Communications leads should seek to identify a designated spokesperson from within the company and position them as an authoritative, trustworthy source of industry information.
Read on to find out how MedTech companies can develop a coherent clinical voice through the trade press and specialist media.
Trade press and specialist media: the channel doing the most unrecognised work.
If peer-reviewed journals are the best channel to build credibility, does the trade press matter?
Yes. Engagement with trade press and specialist media can help develop a clinical spokesperson’s public voice and build association with key topics over time.
MedTech trade publications, including the Health Service Journal (HSJ), Medtech Insight, and Pulse, are regularly read by procurement-adjacent decision makers and should not be ignored in a comprehensive communications strategy. According to HSJ readership data, 18% are commissioners, and an additional 27% are involved in commissioning.
When used strategically, engagement with the trade press can help thought leaders build a credible reputation among NHS trust executives, commissioners, and policy leads. This involves proactive placement of bylined opinion pieces, as well as reactive commentary on key industry developments.
But not all coverage is created equal. Earned coverage will inevitably signal more credibility than transactional or paid placements.
Trade-press pitches must be high-quality and credible.
As AI use rapidly expands, the number of low-quality pitches that trade publications receive has skyrocketed.
In this context, highly selective editors are more inclined to respond to named spokespeople with well-established credentials, underscoring the importance of nurturing a single, authoritative voice in thought leadership.
You should make sure that company spokespeople are well media-trained and prepared for editorial scrutiny and follow-up questions. A positive piece of coverage can quickly turn toxic if thought leaders respond poorly to routine scrutiny.
LinkedIn and digital channels: where to invest and where to stop.
As noted before, you shouldn’t treat LinkedIn and other social media platforms as a way to shape NHS procurement decisions.
But they can be a useful tool for reaching fellow MedTech professionals, policy-adjacent audiences, and potential commercial partners.
So, how does LinkedIn fit into a successful thought leadership strategy?
LinkedIn doesn’t replace engagement with credible, evidence-backed publications. However, it can be successfully used to amplify these efforts.
By sharing published commentary, reacting to announcements from the MHRA and NICE, and demonstrating consistent expertise over time, MedTech companies build their digital reputation and are more likely to become an established name.
Conference keynotes and webinars hosted on LinkedIn Live have grown in popularity post-pandemic and can also be an effective way to reach a wider audience.
But the convening institution matters. A Royal Society of Medicine event or an NHS Confederation session will inevitably be viewed as more credible than a brand-hosted webinar.
Is it okay to post AI-generated content on LinkedIn?
Using AI to help you write thought leadership content for LinkedIn won’t get you banned from the platform, but experienced readers are well-versed in identifying computer-generated content. The 2025 annual Edelman-LinkedIn B2B Thought Leadership Report found that buyers are more receptive to content with a 'human tone'.
To avoid damaging audience trust, you should prioritise authentic, human-written content. Quality matters over quantity, and expert voices are more likely to resonate with clinicians and other MedTech professionals.
Digital channels can help amplify your company’s voice, but they aren’t particularly effective in isolation. To boost thought leadership, they need to sit within a broader, strategically managed communications programme.
Conferences, events, and clinical networks: the channel that compounds over time
The role that sector events play in shaping the MedTech landscape should not be underestimated. Named conferences and forums put thought leaders directly in the room with the people that matter, and can be a valuable opportunity to network with key stakeholders and introduce ideas to the wider health sector.
A MedTech company that invests in event attendance as part of their wider communications strategy has an advantage over those that prioritise content-production alone.
In-person events, including the NHS ConfedExpo (attended by over 2100 senior NHS decision-makers in 2026) and the Royal Society of Medicine’s MedTech programmes (see the 2026-27 'Digital Health Curriculum'), are a particularly effective way to forge public association between a company spokesperson and a specific topic or idea.
There is a compounding effect to this; over time, active participation in sector events builds name recognition, positioning the spokesperson as a reference point for commissioners and fellow clinicians. Journalists will start to turn to them for statements on sector developments, in turn amplifying your company’s profile.
Do spokespeople have to participate in discussions?
Because of the compounding effect, active participation is always more valuable than attendance alone. Chairing an event, sitting on a panel, and booking speaking slots are ways to build a public presence that mere attendance cannot achieve.
Similarly, online and hybrid events fail to replicate the relationship-building dimension of in-person interaction and hold less importance for a MedTech company looking to build influence.
For guidance on how MedTech companies should factor spokesperson event attendance into their longer-term communications strategy, see our B2B corporate engagement page.
Building a channel mix that actually works in 2026
The most important takeaway from this article is the value of credibility. Lack of success in thought leadership is not an issue of content volume. If your high-volume content strategy is not credible or targets the wrong channels, your voice is essentially invisible to those who matter most.
So, what does the channel hierarchy for UK MedTech in 2026 actually look like?
From most influential to least, here's our list:
- Peer-reviewed and clinical publications (credibility building)
- Trade press and events (compounding)
- LinkedIn and digital content (amplifying)
How should you design your communications strategy to maximise influence across all three?
In an ideal world, a communications strategy would work concurrently across the three tiers. However, most UK MedTech companies lack the resources or capacity to manage all these channels well. A realistic target is to focus on fewer things in greater detail.
As AI-generated content continues to saturate all channels with low-effort content, the premium on authentic, evidence-backed expert voice is set to increase. You should resist the temptation to focus your efforts on 'simpler' channels such as LinkedIn, and prioritise the peer-reviewed, clinical publications that actually hold credibility with stakeholders.
Unsure how to invest your time and resources? We can help design a communications strategy that maximises the reach of your MedTech business.
